[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100412800":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":10,"locations":16,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":81,"whyStopped":82,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Participants Treated With Venetoclax + Obinutuzumab",null,"Participants will receive venetoclax (Venclexta) in combination with Obinutuzumab according to local label.",[13],{"name":14,"affiliation":5,"role":15},"ABBVIE INC.","STUDY_DIRECTOR",[17,29,39,48],{"facility":18,"status":10,"city":19,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":10},"Moscow State budget healthcare \u002FID# 226058","Moscow","125284","Russia","RU",{"type":24,"coordinates":25},"Point",[26,27],37.61781,55.75204,{"lat":27,"lon":26},{"facility":30,"status":10,"city":31,"state":32,"zip":33,"country":21,"countryCode":22,"cosmosGeoPoint":34,"geoPoint":38,"contacts":10},"Regional Children's Clinical Hospital of Volgograd \u002FID# 238328","Volgograd","Volgograd Oblast","400138",{"type":24,"coordinates":35},[36,37],44.4976,48.71378,{"lat":37,"lon":36},{"facility":40,"status":10,"city":41,"state":10,"zip":42,"country":21,"countryCode":22,"cosmosGeoPoint":43,"geoPoint":47,"contacts":10},"Russian Research Institute of Hematology and Transfusiology of the FMBA \u002FID# 231127","Saint Petersburg","191024",{"type":24,"coordinates":44},[45,46],30.31413,59.93863,{"lat":46,"lon":45},{"facility":49,"status":10,"city":50,"state":10,"zip":51,"country":21,"countryCode":22,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"Tula Regional Clinical Hospital \u002FID# 231128","Tula","300053",{"type":24,"coordinates":53},[54,55],37.61822,54.19609,{"lat":55,"lon":54},{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100412800","study-of-oral-venetoclax-tablets-in-combination-with-intravenous-obinutuzumab-injection-to-assess-achievement-of-best-response-in-adult-participants-with-chronic-lymphocytic-leukemia-100412800",false,"NCT04655261","Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia","Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Combination With Obinutuzumab in Population of Previously Untreated Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FIRST)","FIRST","Inclusion Criteria:\n\n* Confirmed diagnosis of previously untreated Chronic Lymphocytic Leukemia (CLL).\n* Participant for whom the physician has decided to initiate CLL treatment with Venetoclax combo therapy with Obinutuzumab, according to approved local label up to 4 weeks (28 days) after Obinutuzumab treatment initiation.\n\nExclusion Criteria:\n\n* Contraindications to Venclexta (Venetoclax) as listed on the approved local label in Russian Federation.\n* Creatinine Clearance \\\u003C 30 milliLitres\u002Fminute.\n* Richter syndrome or Transformation of CLL to aggressive non-Hodgkin lymphoma.\n* Participating in a clinical trial with an investigative drug for CLL.","ALL","18 Years",{"count":70,"type":71},5,"ACTUAL","OBSERVATIONAL","Chronic Lymphoid Leukemia (CLL) is the most common type of leukemia (cancer of blood cells) in adults affecting men more so than women. The main objective of this study is to assess the how effective venetoclax (Venclexta) in combination with Obinutuzumab is in treating Chronic Lymphocytic Leukemia (CLL). Effectiveness is assessed by achievement of best response.\n\nVenetoclax is an approved drug developed for the treatment of CLL. Approximately 50 adult participants with previously untreated CLL will be enrolled in approximately 10 to 15 sites in Russian Federation.\n\nParticipants will receive oral venetoclax tablets in combination with intravenous (IV) Obinutuzumab as prescribed by the physician prior to enrolling in this study in accordance to the local practice and label.\n\nThere may be a higher burden for participants in this study compared to standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[75],"Chronic Lymphocytic Leukemia (CLL)",[75,77,78,79,80],"Venetoclax","Venclexta","Obinutuzumab","Cancer","TERMINATED","Lack of Recruitment","2022-10-24",{"date":85,"type":71},"2022-10-26",{"date":87,"type":71},"2020-12-12",{"date":89,"type":71},"2021-11-09",{"name":5,"class":6},4]